BioLineRx and Hemispherian report GLIX1 brain PK/PD data and dose GLIX1-C101 fourth cohort
The companies presented posters at SNO 2026 showing GLIX1 brain penetration and antitumor activity in GBM models, as dosing starts in a fourth cohort with no safety signals reported.
SEC filing, FDA (3)